Abstract:Background and purpose: The production of metallo-ss-lactamases is a major mechanisms adopted by bacterial pathogens to resist carbapenems. Repurposing approved drugs to restore the efficacy of carbapenems represents an efficient and costeffective approach to fight infections caused by carbapenem resistant pathogens. Experimental approach: The nitrocefin hydrolysis assay was employed to screen potential New Delhi metallo-lactamase-1 (NDM-1) inhibitors from a commercially available U.S. Food and Drug Administration (FDA) approved drug library. The mechanism of inhibition was clarified by metal restoration, inductively coupled plasma mass spectrometry (ICP-MS) and molecular dynamics simulation. The in vitro synergistic antibacterial effect of the identified inhibitors with meropenem was determined by the checkerboard minimum inhibitory concentration (MIC) assay, time-dependent killing assay and combined disc test. Three mouse infection models were used to further evaluate the in vivo therapeutic efficacy of combined therapy. Key results: Twelve FDA-approved compounds were initially screened to inhibit the ability of NDM-1 to hydrolyse nitrocefin. Among these compounds, dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid were demonstrated to inhibit all tested metallo-ss-lactamases and showed an in vitro synergistic bactericidal effect with meropenem against metallo-ss-lactamases-producing bacteria. Dexrazoxane, embelin and candesartan cilexetil are metal ion chelating agents, while the inhibition of NDM-1 by nordihydroguaiaretic acid involves its direct binding to the active region of NDM-1. Furthermore, these four drugs dramatically rescued the treatment efficacy of meropenem in three infection models. Conclusions and implications: Our observations indicated that dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid are promising carbapenem adjuvants against metallo-ss-lactamases-positive carbapenem resistant bacterial pathogens.

Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases

Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors

Quinolinyl sulfonamides and sulphonyl esters exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Structural and Mechanistic Insights into NDM-1 Catalyzed Hydrolysis of Cephalosporins.

Thiosemicarbazones exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Aromatic Schiff bases confer inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Discovery of Thiosemicarbazone Derivatives As Effective New Delhi Metallo-Β-lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates.

N-acylhydrazones confer inhibitory efficacy against New Delhi metallo-β-lactamase-1

Novel Metallo‐β‐lactamases Inhibitors Restore the Susceptibility of Carbapenems to New Delhi Metallo‐lactamase‐1 (ndm‐1)‐harbouring Bacteria

Design of Dipicolinic Acid Derivatives As New Delhi Metallo-Β-lactamase-1 Inhibitors Using a Combined Computational Approach.

Novel Mercapto Propionamide Derivatives with Potent New Delhi Metallo-β-Lactamase-1 Inhibitory Activity and Low Toxicity

Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).

Systematic research of H2dedpa derivatives as potent inhibitors of New Delhi Metallo-β-lactamase-1

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates

Structure-based computational study of the hydrolysis of New Delhi metallo-β-lactmase-1

Structure-Based Computational Study Of The Hydrolysis Of New Delhi Metallo-Beta-Lactmase-1

Discovery of the Novel Inhibitor Against New Delhi Metallo-β-Lactamase Based on Virtual Screening and Molecular Modelling.

Pterostilbene Restores Carbapenem Susceptibility in New Delhi Metallo‐β‐lactamase‐producing Isolates by Inhibiting the Activity of New Delhi Metallo‐β‐lactamases

First Identification of Isatin-Β-thiosemicarbazones As Novel Inhibitors of New Delhi Metallo-Β-lactamase-1: Chemical Synthesis, Biological Evaluation and Molecular Simulation

Discovery of Novel New Delhi Metallo-Β-lactamases-1 Inhibitors by Multistep Virtual Screening.

Discovery of Isatin-Β-methyldithiocarbazate Derivatives As New Delhi Metallo- Β-Lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates